Though Daiichi Sankyo (OTCMKTS: DSNKY) and Sanofi SA (NASDAQ: SNY) came forward to help produce other pharmas’ COVID-19 shots, the companies are calling it quits on their own, separate vaccine alliance in Japan. Daiichi Sankyo has decided to
Sanofi SA (NASDAQ: SNY) is dropping a major investment into its supply chain by shelling C$925 million to build a new manufacturing facility in Toronto. The new facility will be operational by 2026 and provide additional
The FDA has approved Janssen’s a unit of Johnson & Johnson (NYSE: JNJ) Ponvory (ponesimod) for relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Ponvory is a
Global Blood Therapeutics Inc (NASDAQ: GBT) has exclusively in-licensed worldwide rights to two early-stage research programs in sickle cell disease from Sanofi SA (NASDAQ: SNY). One program pursues a novel anti-sickling mechanism, and the other leverages a new approach
Sanofi SA (NASDAQ: SNY) and Translate Bio Inc (NASDAQ: TBIO) have started a human trial of their mRNA COVID-19 vaccine candidate, dubbed MRT5500. The event has triggered a milestone payment of $25 million to Translate Bio. The Phase 1/2
U.S. President Joe Biden will announce that Merck & Co (NYSE: MRK) will help manufacture its rival Johnson & Johnson’s (NYSE: JNJ) newly authorized coronavirus vaccine to boost the supply, Washington Post reports. The officials started looking for additional manufacturing
Health Canada has approved Sanofi’s SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) DUPIXENT (dupilumab injection) for the treatment of moderate-to-severe atopic dermatitis in children aged six to 11 years whose disease is not adequately controlled with